Drugs / Desidustat
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04667533 | Nov 2020 → Mar 2022 | anemia due to chronic disorder, chemotherapy-induced toxicity | Zydus Lifesciences Limited | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04463602 | Jul 2020 → Jan 2021 | COVID-19 | Zydus Lifesciences Limited | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT05515367 | Apr 2023 → Jun 2025 overdue | anemia due to chronic disorder, chronic kidney disease | Zydus Lifesciences Limited | Recruiting | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04215120 Comparator | Jan 2020 → Sep 2021 | end stage renal failure | Zydus Lifesciences Limited | Completed | No outcome recorded |
| Phase 3 | NCT04012957 Comparator | Jul 2019 → Aug 2021 | anemia, chronic kidney disease | Zydus Lifesciences Limited | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Desidustat | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04215120 ↗ |
| Known as | ZYAN1 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650314 ↗ |
| Modality | Small molecule | — CHEMBL4650314 ↗ |
| Route | Oral | “Desidustat oral tablet” NCT04012957 ↗ |